<DOC>
	<DOCNO>NCT01143545</DOCNO>
	<brief_summary>Background : - Certain type lung , esophageal , thymic cancer mesotheliomas specific antigen ( protein molecule ) surface . Research study show give vaccine contains antigens similar may cause immune response , may keep tumor grow . Researchers also interest determine whether chemotherapy drug cyclophosphamide anti-inflammatory drug celecoxib may help vaccine work well , particularly patient lung cancer . Objectives : - To evaluate safety effectiveness tumor cell vaccine combination cyclophosphamide celecoxib patient cancer involve chest . Eligibility : - Individuals least 18 year age surgery small cell non-small cell lung cancer , esophageal cancer , thymoma thymic carcinoma , malignant pleural mesothelioma . Design : - Following recovery surgery , chemotherapy , radiation , participant leukapheresis collect lymphocyte ( white blood cell ) test . - Participants receive celecoxib cyclophosphamide take twice day home , 7 day vaccine . - Participants vaccine clinical center ( one two shot per month 6 month ) , stay clinic 4 hour vaccine . Participants keep diary home side effect vaccine , continue take cyclophosphamide celecoxib . - One month sixth vaccine , participant provide another blood sample testing , test satisfactory return clinic every 3 month 2 additional vaccine . - Participants return clinic follow-up physical examination , lab test , scan every 3 month 2 year every 6 month 3 year .</brief_summary>
	<brief_title>Pilot Study Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide Celecoxib Patients Undergoing Resection Lung Esophageal Cancers , Thymic Neoplasms , Malignant Pleural Mesotheliomas</brief_title>
	<detailed_description>Background : During recent year , cancer-testis ( CT ) antigens emerged attractive target cancer immunotherapy . Whereas lung esophageal cancer , well malignant pleural mesothelioma express variety CT antigens , immune response antigens appear uncommon patient malignancy , possibly due low-level , heterogeneous antigen expression , well immunosuppressive regulatory T cell . Our published study indicate numerous CT antigen induce tumor cell DNA demethylating agent histone deacetylase ( HDAC ) inhibitor . Conceivably , vaccination cancer patient allogeneic tumor cell express high level multiple CT antigens combination depletion T regulatory cell induce broad immunity antigen . In order examine issue , patient lung esophageal cancer , thymic neoplasm , primary thoracic sarcoma , malignant pleural mesothelioma vaccinate irradiated K562 erythroleukemia cell express GM-CSF ( K562-GM ) follow completion appropriate combine modality therapy . Vaccines administer conjunction metronomic oral cyclophosphamide ( 50 mg PO BID x 7dq 14d ) , celecoxib ( 400 mg PO BID ) . Serologic response variety recombinant CT antigens well cell-mediated recognition autologous tumor cell EBVtransformed B cell assessed vaccination . Primary Objectives : -To assess safety K562-GM allogeneic tumor cell vaccine combination oral metronomic cyclophosphamide celecoxib thoracic oncology patient . Eligibility : - Patients histologically cytologically proven small cell non-small cell lung cancer , esophageal cancer , thymoma thymic carcinoma , primary thoracic sarcoma , malignant pleural mesothelioma evidence disease ( NED ) minimal residual disease ( MRD ) primary site follow standard multimodality therapy . - Patients must 18 year old ECOG performance status 0 - 2 , without evidence unstable decompensated myocardial disease . Patients must adequate pulmonary reserve evidence FEV1 DLCO equal great 30 % predict ; pCO2 less 50 mm Hg pO2 great 60 mm Hg room air ABG ; immunosuppressive medication except inhaled corticosteroid time vaccination commences . - Patients must platelet count great 100,000 , ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin &lt; 1.5 x upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) time vaccination commences . Design : - Following recovery standard combine modality therapy , patient evidence disease minimal residual disease vaccinate via subcutaneous intradermal injection 1x10 ( 8 ) irradiate K562-GM-tumor cell periodically 6 month . Sterility , potency identity vaccine prep confirm administration . - Vaccines administer conjunction metronomic oral cyclophosphamide celecoxib . - Systemic toxicity , immunologic response therapy record . Pre post vaccination serologic responses standard panel CT antigens well cell mediate responses epigenetically-modified autologous EBV-transformed B autologous tumor cell ( available ) assess vaccination . - Numbers/percentages function T regulatory cell peripheral blood assess , , vaccination . - Patients follow clinic routine staging scan disease recurrence . - As exact set comparison analysis perform determine follow completion trial , base limited number patient , analysis consider exploratory hypothesis generate rather definitive . - Approximately 25 patient accrue trial .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients primary small cell nonsmall cell lung cancer , esophageal cancer , thymoma , thymic carcinoma , primary sarcoma chest , pleural mesothelioma evidence disease ( NED ) minimal residual disease ( MRD ) primary site follow standard multimodality therapy . 2 . Patients must evaluate within 52 week follow completion standard therapy show evidence disease time . 3 . Patients intracranial metastasis , treat surgery radiation therapy may eligible study provide evidence active disease requirement anticonvulsant therapy steroid follow treatment . 4 . Patients must ECOG performance status 0 2 . 5 . Patients must 18 year age old due unknown effect immunologic response germ cellrestricted gene product childhood adolescent development . 6 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 8g/dl ( patient may receive transfusion meet parameter ) PT within 2 second ULN Total bilirubin &lt; 1.5 time upper limit normal Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . 7 . Seronegative HIV antibody . Note : The experimental treatment evaluate protocol depend intact immune system . Patients HIV seropositive decrease immune competence thus may less responsive experimental treatment . 8 . Seronegative active hepatitis B , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen RTPCR HCV RNA negative . 9 . Patients must willing practice birth control four month follow treatment . 10 . Patients must willing sign inform consent . 11 . Patients must willing sign inform consent . EXCLUSION CRITERIA : 1 . Patients initially render NED MRD combine modality therapy exhibit disease progression prior initiation vaccination exclude study . 2 . Patients receive two systemic cytotoxic treatment regimens thoracic malignancy time vaccination commences exclude . 3 . Patients require corticosteroid ( inhale ) exclude . 4 . Patients life expectancy le 12 month exclude . 5 . Patients receive warfarin anticoagulation , transfer agent enoxaparin dabigatran , anticoagulant hold 24 hour exclude . 6 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated CHF ( &gt; NYHA Class II ) , myocardial infarction within 6 month study exclude . 7 . Patients cardiac disease may exclude discretion PI follow consultation Cardiology consultant . 8 . Patients follow pulmonary function abnormality exclude : FEV , &lt; 30 % predict ; DLCO &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . 9 . Pregnant and/or lactate woman exclude due unknown , potentially harmful effect immune response CTX antigens stem cell protein may express placenta , fetus , neonate . 10 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 11 . Patients type primary immunodeficiency exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 25, 2017</verification_date>
	<keyword>Cancer Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Adjuvant Therapy</keyword>
	<keyword>Surgical Intervention</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Thymic Carcinoma</keyword>
	<keyword>Malignant Pleural Mesothelioma</keyword>
</DOC>